Objetivo StemCell2MAX is a biotechnology start-up that owns a proprietary solution for multiplying blood stem cells. Blood stem cells are required for both research and blood cancer treatment, but are scarce resulting in limited transplants (34% of patients do not find a donor), patient death (6-15%) and limitations at research level (12.500 groups lack cells for their studies). StemCell2MAX addresses this enormous demand from patients, cord blood banks, hospitals and researchers in an estimated €3 billion potential market (33% CAGR). No solution for blood stem cell multiplication is available for clinical purposes and those that are currently used for research purposes compromise cell quality. StemCell2MAX has developed a product that multiplies these cells while assuring their quality (20x better results compared to state of the art, as published in Nature). Currently, StemCell2MAX markets a research use only product (€600M market) with a growing sales track record, both in EU and USA. Following the technology’s market acceptance and scientific recognition, StemCell2MAX is preparing their solution for the €2.4B clinical market. The innovation is protected in EU, USA and Japan for blood stem cell maintenance, expansion or transplantation, for both research and clinical use. StemCell2MAX won the “most investable company” award during the first Horizon 2020 – Invest Horizon Global Investor Summit in November 2015.Specific objectives:• To develop a business plan and marketing strategy for clinical application• To explore strategic partnerships for development and commercialisation• To explore the clinical validation strategy/clinical trial design• To develop a strategic development plan in agreement with reimbursement policies Expected outcomes:• A business plan and optimal route-to-market, including partnering strategy for further development • Clinical trial strategy in compliance with all regulatory requirements Ámbito científico medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugssocial scienceseconomics and businessbusiness and managementbusiness modelsmedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesclinical medicineoncologymedical and health sciencesclinical medicinetransplantation Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Tema(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Convocatoria de propuestas H2020-SMEInst-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2016-2017 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador GROWINGFORMULA LDA Aportación neta de la UEn € 50 000,00 Dirección BIOCANT PARK NUCLEO 04, LOTE 02 3060 197 CANTANHEDE Portugal Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región Continente Centro (PT) Região de Coimbra Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00
